Cancellation and short postponement of primary hip or knee arthroplasty does not influence postoperative joint specific function or health related quality of life
European Journal of Orthopaedic Surgery & Traumatology · 2024
DOI: 10.1007/s00590-024-04088-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Orthopaedic Surgery & Traumatology, 2024. Verfasst von J Edwards und 4 weiteren Autor:innen. Beteiligte Einrichtung: Southwest London Orthopaedic Elective Centre, Epsom, UK. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The effect of cancellation and postponement of primary total hip arthroplasty (THA) or knee arthroplasty (TKA) on patient outcomes is unclear. The aim was to assess whether cancellation and delay to arthroplasty was associated with worse joint specific function and quality of life (QoL) 1-year postoperatively. METHODS: A single centre retrospective case-control study was performed for all patients planned to undergo THA or TKA in 2019. A total of 3133 arthroplasties were scheduled for 2019 (1484 THA, 1649 TKA), of which 344 (11.0%) were cancelled (136 THA [9.2%], 208 TKA [12.6%]). Pre-operative and one-year post-operative EuroQol (EQ-5D) and Oxford hip (OHS) or knee (OKS) scores were collected. RESULTS: The median time between the date of cancellation and the subsequent operation was 46.0 days for TKA and 45.5 days for THA. The cancelled group were more likely to be male (odds ratio [OR] 1.23, p = 0.03), older (mean difference [MD] 1.19, p = 0.03), with a higher ASA grade (OR 1.88 [ASA 3], OR 5.3 [ASA 4], p = 0.001) or planned for a TKA (OR 1.41, p = 0.003). There were no differences in pre-operative OKS (mean difference [MD] 0.19, p = 0.828) or EQ-5D (MD 0.028, p = 0.394) or in the one-year postoperative OKS (MD 1.51, p = 0.064) or EQ-5D (MD 0.041, p = 0.067) between groups undergoing TKA. However, cancelled THA patients had lower pre-operative OHS (MD 2.73, p = 0.018) and EQ-5D (MD 0.134, p = 0.0017) but at one-year postoperatively there was no difference in the absolute OHS (MD 2.07, p = 0.052) or EQ5D (MD 0.04, p = 0.142). The improvement in hip EQ-5D was greater (MD 0.096, p = 0.016) in the cancelled group. CONCLUSION: Cancellation and short delay did not influence joint specific outcome or QoL following THA or TKA at one-year. Preoperative hip specific pain, function and QoL were worse in cancelled THA patients, suggesting deterioration while waiting for their surgery, but this did not affect their postoperative outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Southwest London Orthopaedic Elective Centre, Epsom, UK.
- Southwest London Orthopaedic Elective Centre, Epsom, UK. nickclement@doctors.org.uk.
- Edinburgh Orthopaedics, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK. nickclement@doctors.org.uk.
Zitieren
APA
Edwards, J., Clement, N. D., Afzal, I., Jones, S., & Sochart, D. H. (2024). Cancellation and short postponement of primary hip or knee arthroplasty does not influence postoperative joint specific function or health related quality of life. European Journal of Orthopaedic Surgery & Traumatology. https://doi.org/10.1007/s00590-024-04088-1
Vancouver
Edwards J, Clement ND, Afzal I, Jones S, Sochart DH. Cancellation and short postponement of primary hip or knee arthroplasty does not influence postoperative joint specific function or health related quality of life. European Journal of Orthopaedic Surgery & Traumatology. 2024. doi:10.1007/s00590-024-04088-1
BibTeX
@article{Edwards2024,
author = {Edwards, J and Clement, N D and Afzal, I and Jones, S and Sochart, D H},
title = {Cancellation and short postponement of primary hip or knee arthroplasty does not influence postoperative joint specific function or health related quality of life},
journal = {European Journal of Orthopaedic Surgery & Traumatology},
year = {2024},
doi = {10.1007/s00590-024-04088-1}
}
EUVIMED